Aventis' Actonel Reaches 10% Of New Weekly Prescriptions For Osteoporosis
Executive Summary
Aventis' share of new prescriptions for its osteoporosis therapy Actonel is almost 10%, Investor Relations Director Arvind Sood said during a third quarter earnings call Nov. 9.
You may also be interested in...
Merck Fosamax Once-Weekly Is Priced Same Per Day As Its Daily Strengths
Merck's new once-weekly 70 mg Fosamax formulation is set at the same price per day of therapy as the daily 5 mg and 10 mg formulations of the osteoporosis drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials